Oakworth Capital Inc. Grows Stock Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Oakworth Capital Inc. lifted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 165,074 shares of the exchange traded fund’s stock after purchasing an additional 2,563 shares during the period. SPDR S&P Biotech ETF comprises about 1.2% of Oakworth Capital Inc.’s holdings, making the stock its 20th largest holding. Oakworth Capital Inc. owned about 0.22% of SPDR S&P Biotech ETF worth $14,739,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Verity Asset Management Inc. raised its stake in SPDR S&P Biotech ETF by 7.9% in the third quarter. Verity Asset Management Inc. now owns 17,228 shares of the exchange traded fund’s stock valued at $1,258,000 after buying an additional 1,266 shares in the last quarter. Prime Capital Investment Advisors LLC raised its stake in SPDR S&P Biotech ETF by 52.6% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 6,464 shares of the exchange traded fund’s stock valued at $577,000 after buying an additional 2,228 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at $533,000. United Capital Management of KS Inc. raised its stake in SPDR S&P Biotech ETF by 1.8% in the fourth quarter. United Capital Management of KS Inc. now owns 104,048 shares of the exchange traded fund’s stock valued at $9,290,000 after buying an additional 1,831 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at $10,587,000.

SPDR S&P Biotech ETF Stock Down 0.8 %

SPDR S&P Biotech ETF stock traded down $0.67 during midday trading on Wednesday, reaching $84.94. The company’s stock had a trading volume of 9,694,925 shares, compared to its average volume of 11,681,729. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52. The company has a market cap of $6.60 billion, a P/E ratio of 11.47 and a beta of 1.08. The business has a 50-day simple moving average of $93.86 and a 200-day simple moving average of $84.12.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.